KBI acquires Elion to establish ‘the most powerful analytical capabilities’ in biopharma CDMO industry, says CEO

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/JK1991)
(Image: iStock/JK1991)

Related tags Biotechnology Research triangle park

KBI Biopharma has acquired Elion Labs as it continues to expand its biophysical and analytical characterization capabilities.

Louisville, CO-based Elion Labs is a contract analytical organization. The company’s services include analytical method development, qualification and validation, characterization of biologics, and comprehensive data analysis including visualization and interpretation of complex data sets.

Through the acquisition of Elion, in combination with our acquisition of Alliance Protein Labs in 2017, KBI has established the most powerful analytical capabilities in the biopharmaceutical CDMO industry​,” KBI CEO Tim Kelly told us. 

Terms of the transaction were not disclosed.

All of Elion’s staff will join KBI, including Elion co-founders, who will continue to oversee operations at the Louisville, CO facility, which will complement KBI’s facility in Boulder, CO, according to the company.

KBI also operates facilities in Durham and Research Triangle Park, NC, The Woodlands, TX, and San Diego, CA, across which the company has expanded its capabilities over the last 12 months.

In addition to expanding its Durham, NC and Boulder, CO facilities, KBI also added cell therapy development and manufacturing capabilities at its The Woodlands, TX, facility.

KBI has also worked to integrate Selexis’ cell line development technology into its mammalian cell culture development and manufacturing platforms in NC, after its parent company, JSR Life Sciences, purchased the cell line developer in June​ of last year.

Also last year, KBI purchased the San Diego, CA-based contract research organization (CRO) Alliance Protein Laboratories.

Our clients will benefit from greatly expanded expertise and infrastructure to accelerate the development of their most impactful biopharmaceutical products as they seamlessly access the unique analytical capabilities and talent across our sites​,” said Kelly.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us


View more